Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction

Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights from the EMPEROR-Reduced Trial

(2020) Faiez Zannad et al.   CIRCULATION

SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials

(2020) Faiez Zannad et al.   LANCET

Dapagliflozin in Patients with Chronic Kidney Disease

(2020) Hiddo J.L. Heerspink et al.   NEW ENGLAND JOURNAL OF MEDICINE

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

(2019) Vlado Perkovic et al.   NEW ENGLAND JOURNAL OF MEDICINE

GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Meta-Analysis of Treatment Effects of Randomized Controlled Trials

(2019) Lesley A. Inker et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency

(2019) Andrew S. Levey et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure

(2018) Kevin Damman et al.   JACC-Heart Failure

Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus

(2013) David Z.I. Cherney et al.   CIRCULATION

Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis

(2013) K. Damman et al.   EUROPEAN HEART JOURNAL